Suchergebnisse - "Tabernero, J"

PubPharm (16)

1

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

enthalten in: ESMO open | 2022

von Borazanci, E. | Schram, A. | Garralda, E. | +20

2

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

3

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Arnold, D. | Fuchs, C. | Tabernero, J. | +16

4

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Arnold, D. | Lueza, B. | Douillard, J. | +9

CommentIn: Ann Oncol. 2017 Aug 1;28(8):1685-1686. - PMID 28541394

5

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Boeckx, N. | Koukakis, R. | Op de Beeck, K. | +7

CommentIn: Ann Oncol. 2017 Aug 1;28(8):1685-1686. - PMID 28541394

6

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

7

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6

8

Final results from PRIME : randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Douillard, J. | Siena, S. | Cassidy, J. | +18

9

Genomic aberrations in the FGFR pathway : opportunities for targeted therapies in solid tumors

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Dienstmann, R. | Rodon, J. | Prat, A. | +7

10

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Cohn, A. | Tabernero, J. | Maurel, J. | +15